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Background: Osteosarcoma is the most common primary malignant tumor in children and young adults, and its
treatment requires effective therapeutic approaches because of a high mortality rate for lung metastasis. Epithelial
to mesenchymal transition (EMT) has received considerable attention as a conceptual paradigm for explaining the
invasive and metastatic behavior during cancer progression. The cysteine-rich angiogenic inducer 61 (Cyr61) gene,
a member of the CCN gene family, is responsible for the secretion of Cyr61, a matrix-associated protein that is
involved in several cellular functions. A previous study showed that Cyr61 expression is related to osteosarcoma
progression. In addition, Cyr61 could promote cell migration and metastasis in osteosarcoma. However, discussions
on the molecular mechanism involved in Cyr61-regulated metastasis in osteosarcoma is poorly discussed.
Results: We determined that the expression level of Cyr61 induced cell migration ability in osteosarcoma cells. The
Cyr61 protein promoted the mesenchymal transition of osteosarcoma cells by upregulating mesenchymal markers
(TWIST-1 and N-cadherin) and inhibiting the epithelial marker (E-cadherin). Moreover, the Cyr61-induced cell migration
was mediated by EMT. The Cyr61 protein elicited a signaling cascade that included αvβ5 integrin, Raf-1, mitogen-
activated protein kinase (MEK), extracellular signal-regulated kinase (ERK), and Elk-1. The reagent or gene knockdown of
these signaling proteins could inhibit Cyr61-promoted EMT in osteosarcoma. Finally, the knockdown of Cyr61
expression obviously inhibited cell migration and repressed mesenchymal phenotypes, reducing lung metastasis.
Conclusion: Our results indicate that Cyr61 promotes the EMT of osteosarcoma cells by regulating EMT markers via a
signal transduction pathway that involves αvβ5 integrin, Raf-1, MEK, ERK, and Elk-1.
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Osteosarcoma is the most prevalent primary malignant
bone tumor that affects mainly children and adolescents.
Osteosarcoma treatment has undergone dramatic chan-
ged drastically over the past 20 years, whatever the sur-
vival rate shows limited. Thus far, the 5-year survival
rate is approximately 20% with surgical treatment alone.
Moreover, half of the patients often exhibit pulmonary
metastasis, which results in high patient mortality [1].
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unless otherwise stated.case for improving the prognosis and long-term survival.
However, recurrence frequently manifests as pulmonary
metastasis or, less frequently, metastasis to distant bones
or as a local recurrence [2-4]. Thus, a novel strategy that
would effectively inhibit metastasis, particularly to the
lungs, from the primary osteosarcoma site is highly
desirable.
Cancer metastasis is a critical step in tumor progres-
sion and a major cause of mortality in cancer patients.
Epithelial to mesenchymal transition (EMT) has received
considerable attention as a conceptual paradigm for
explaining invasive and metastatic behavior during can-
cer progression [5]. EMT is a normal physiologic process
in vertebrate development and tissue homeostasis, and is
increasingly considered to be involved in disease states
such as tissue fibrosis and cancer [6]. EMT is a process. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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converted into a mesenchymal phenotype [5,7]. A hall-
mark of EMT is the loss of epithelial characteristics,
such as a decrease in the expression of the cell adhesion
molecular E-cadherin and the acquisition of a mesen-
chymal phenotype accompanied by increased vimentin
expression. EMT-related transcription factors such as
TWIST-1, snail, slug, ZEB1, and ZEB2 orchestrate the
EMT, and enable the early steps of metastasis, which
consist primarily of local invasion and the subsequent
dissemination of tumor cells to distant sites [8]. These
transcription factors repress E-cadherin expression by
binding to the E-box in the E-cadherin gene promoter,
and consequently promote EMT [9-13]. Substantial evi-
dence has indicated that osteosarcoma exhibits EMT-
like states, characterized by changes in the expression of
EMT-related transcription factors, such as TWIST-1, snail,
and ZEBs, which are involved in the complex pathogenesis
of osteosarcoma [14]. Targeting these transcription factors
may provide a novel opportunity in osteosarcoma treat-
ment by controlling metastasis.
Cysteine-rich 61 (Cyr61) is the first discovered member
of the CCN family [15], which comprises Cyr61/CCN1,
connective tissue growth factor (CTGF/CCN2), nephroblas-
toma overexpressed (Nov/CCN3), Wisp-1/elm1 (CCN4),
Wisp-2/rCop1 (CCN5), and Wisp-3 (CCN6). All members
of the CCN family share a common domain structure and
exert variant cellular functions such as the regulation of
cell division, chemotaxis, apoptosis, adhesion, motility,
and ion transport [16-18]. The Cyr61 protein has been re-
ported to mediate cell adhesion, stimulate chemostasis,
augment growth factor-induced DNA synthesis, foster cell
survival, and enhance angiogenesis [19,20]. Previous stud-
ies have found that Cyr61 expression is associated with
breast cancer, pancreatic cancer, and gliomas [21-24].
Downregulated Cyr61 expression has been reported in
prostate cancer, uterine leiomyoma, rhabdomyosarcoma,
and non-small-cell lung carcinoma [25-28]. The ambigu-
ous expression of Cyr61 in different types of cancer sug-
gests that Cyr61 may exert a sophisticated function
depending on the cellular context.
Previous studies have shown that Cyr61 modulates cell
migration and invasion in human cancer cells [29-31].
Moreover, Cyr61 has been proposed to play a pivotal
role in osteogenesis and an aberrant expression of Cyr61
is associated with osteosarcoma progression and lung
metastasis [32]. Nevertheless, whether Cyr61 promotes
EMT in osteosarcoma remains unclear. This paper is the
first to provide evidence that Cyr61 increases EMT in
osteosarcoma and contributes to lung metastasis. In
addition, Cyr61-promoted EMT is mediated by αvβ5 in-
tegrin, Raf-1, mitogen-activated protein kinase kinase
(MEK), extracellular signal-regulated kinase (ERK), and
Elk-1 signaling pathways, and may be involved in theregulation of EMT in osteosarcoma. Finally, we show
that the knock-down of Cyr61 expression inhibits lung
metastasis in osteosarcoma. In conclusion, our findings
revealed that Cyr61 regulated EMT and thus promoted
lung metastasis in osteosarcoma.
Results
Cyr61 overexpression was associated with high migration
potential in osteosarcoma
A previous study indicated that Cyr61 overexpression is
correlated with a poor prognosis, and promotes metastasis
in osteosarcoma [33]. However, the molecular mechanism
involved in Cyr61-induced metastasis in osteosarcoma has
not been thoroughly investigated. We clarified the correl-
ation between Cyr61 and cell migration ability in osteosar-
coma. We selected the high-migration-ability MG63 cell
sublines by using the Transwell assay, and our results
revealed that the mRNA and protein expression levels of
Cyr61 increased in the high-migration-prone subline
(MG63, M7, and M10) (Figure 1A-C, respectively). More-
over, treating osteosarcoma cells (MG63) with recombin-
ant Cyr61 dramatically increased the cell migration ability,
demonstrated using a migration assay and a wound heal-
ing assay (Figure 1D-E). Finally, pretreating MG63 cells
with a Cyr61-neutralized antibody evidently abolished
Cyr61-induced cell migration (Figure 1F). These results
indicate that Cyr61 plays a pivotal role in osteosarcoma
migration ability.
Cyr61 regulated EMT markers and promoted
mesenchymal transformation
Previous studies have proposed that EMT is associated
with cancer cell migration, tumor metastasis, and pro-
gression [7,34]. To contribute to these observations, we
investigated whether Cyr61-induced migration is regu-
lated by the mesenchymal transformation of osteosar-
coma. We compared epithelial and mesenchymal cell
markers in MG63 cells and other sublines. The expres-
sion patterns of the EMT markers were found to be
tightly correlated with Cyr61 expression in these sublines.
The most migratory subline, MG63 (M10), expressed
mesenchymal markers (N-cadherin and TWIST-1), but
fewer epithelial markers (E-cadherin) (Figure 2A&B).
Moreover, the most migratory subline MG63 (M10),
showed a loose cell contact and spindle-shaped morph-
ology representative of EMT, but not a cobblestone-like
morphology in parental MG63 cells (Figure 2C). To clarify
the role of Cyr61 in the EMT of osteosarcoma, the MG63
cells were treated with recombinant Cyr61. The results in-
dicated that Cyr61 induced the expression of mesenchymal
markers (N-cadherin and TWIST-1), but repressed an epi-
thelial marker (E-cadherin) in a time- and dose-dependent
manner (Figure 2D-G). Finally, we used the TWIST-1
short hairpin RNA (shRNA) to demonstrate whether
Figure 1 Cyr61 is associated with the cell migration phenotype. (A) MG63 cells and its sublines were selected according to description in
the Methods section, and cell migration was examined using the Transwell assay. (B and C) Total mRNA and proteins were extracted from the
MG63 cells and its sublines, and Cyr61 expression was detected using qRT-PCR and western blotting. (D and E) Cells were incubated with Cyr61
(1-30 ng/mL) for 24 h, and cell migration was measured using the Transwell and wound-healing assays. (F) MG63 cells were pretreated with
anti-Cyr61 mAb (25-200 ng/mL) for 24 h. Cell migration was measured after 24 h using the Transwell assay. The results are expressed as the
mean ± SEM of triplicate samples. *P <0.05 compared with the control group.
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regulation, and the results revealed that transfection with
TWIST-1 shRNA dramatically inhibited Cyr61-induced
cell migration in osteosarcoma (Figure 2H). These results
revealed that Cyr61 could promote cell migration by pro-
moting the mesenchymal transformation of osteosarcoma.
Cyr61 promoted mesenchymal transformation through
integrin αvβ5 in osteosarcoma
Numerous reports have indicated that the CCN family in-
teracts with integrin receptors to modulate cell biological
functions [35]. Therefore, we investigated whether integ-
rins were involved in Cyr61-promoted mesenchymal trans-
formation in osteosarcoma. Pretreating MG63 cells with
the anti-αvβ5 integrin antibody (3 μg/mL) for 30 min
markedly inhibited Cyr61-induced cancer cell migration;
however, the anti-αvβ3 integrin antibody did not (Figure 3A).
Similarly, treating MG63 cells with the anti-αvβ5 integrin
antibody inhibited the EMT markers (E-cadherin, N-
cadherin, and TWIST-1) from shifting, which were regu-
lated with Cyr61 treatment (Figure 3B-C). To confirm the
role of integrin αvβ5 in Cyr61-promoted EMT in osteosar-
coma, shRNAs that target integrin αv and β5 were used.
The results showed that transfection with these shRNAs
inhibited Cyr61-induced cell migration and the shift ofEMT markers (Figure 3D-F). The authors of a previous re-
port discussed the pivotal role of integrin αv in EMT [36].
We used MFG-E8 (a ligand of integrin αvβ5) to improve
the role of integrin αvβ5 in the EMT of osteosarcoma.
The result indicated that MFG-E8 induced the shift of
EMT markers and cell migration ability, but osteopontin
(a ligand of integrin αvβ3) did not (Figure 3G-I). In sum-
mary, these results clearly showed that Cyr61-promoted
mesenchymal transformation is mediated by integrin αvβ5.
Cyr61 promoted mesenchymal transformation via the
Raf-1/MEK/ERK signaling pathway
Previous studies have demonstrated that Ras/Raf-1/ERK
signaling plays a crucial role in EMT regulation in sev-
eral cancers [37-39]. Therefore, we evaluated the role of
Raf-1/MEK/ERK signaling in Cyr61-promoted mesen-
chymal transformation. Our results indicated that pre-
treating MG63 cells with a Raf-1 inhibitor (Gw5074),
MEK inhibitor (PD98059), and ERK inhibitor (U0126)
dramatically reduced Cyr61-induced cell migration and
the shift of EMT markers (Figure 4A-C). Moreover,
treating MG63 cells with Cyr61 induced the phosphoryl-
ation of Raf-1, MEK, and ERK in a time-dependent man-
ner (Figure 4D). In addition, transfecting MG63 cells
with Raf-1 shRNA, dominant-mutant MEK (DN-MEK),
Figure 2 Cyr61 regulates EMT markers and promotes mesenchymal transformation. (A and B) Total mRNA and proteins were extracted
from the MG63 cells and its sublines, and the expression levels of TWIST-1, N-cadherin and E-cadherin were detected using qRT-PCR and western
blotting. (C) Phase-contrast images of the MG63 cells and their sublines were photographed. The subconfluent cultures were shown to indicate
the morphological differences between MG63 and the sublines. (D and E) Cells were incubated with Cyr61 (1-30 ng/mL) for 24 h, total mRNA
and proteins were extracted from the MG63 cells, and the expression levels of TWIST-1, N-cadherin, and E-cadherin were detected using qRT-PCR
and western blotting. (F and G) Cells were incubated with Cyr61 (10 ng/mL) for different time (0-24 h), total mRNA and proteins were extracted
from the MG63 cells, and the expression levels of TWIST-1, N-cadherin and E-cadherin were detected using qRT-PCR and western blotting. (H) MG63
cells were transfected with TWIST-1 shRNA or control shRNA for 24 h, followed by treatment with Cyr61 (10 ng/mL) for 24 h, and cell migration was
analyzed using the Transwell assay. The results are expressed as the mean ± SEM of triplicate samples. *P <0.05 compared with the control group, and
#P <0.05 compared with Cyr61 treatment.
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mediated cell migration and the shift of EMT markers
(Figure 4E-G). Furthermore, pretreating of cells with the
anti-αvβ5 integrin antibody reduced Cyr61-induced Raf-1
phosphorylation (Figure 4H), and pretreating cells with a
Raf-1 inhibitor (Gw5074) reduced Cyr61-induced MEK
phosphorylation (Figure 4I). Therefore, these results revealedthat αvβ5 integrin, Raf-1, MEK, and ERK were involved in
Cyr61-promoted mesenchymal transformation.
Cyr61 promoted mesenchymal transformation via the
Elk-1 signaling pathway
The Elk-1 factor is a major downstream cytosolic tran-
scription factor of ERK signaling, and the translocation
Figure 3 Cyr61-promoted EMT is mediated by integrin αvβ5. (A) MG63 cells were pretreated with anti-integrin αvβ3 or αvβ5 mAb (3 μg/mL)
for 30 min, followed by stimulation with Cyr61 (10 ng/mL) for 24 h. Cell migration was measured after 24 h using the Transwell assay. The IgG
served as the negative control. (B and C) MG63 cells were pretreated with anti-integrin αvβ3 or αvβ5 mAb (3 μg/mL) for 30 min, followed by
stimulation with Cyr61 (10 ng/mL) for 24 h. Total mRNA and proteins were extracted from the MG63 cells, and the expression levels of TWIST-1,
N-cadherin and E-cadherin were detected using qRT-PCR and western blotting. (D) MG63 cells were transfected with integrin αvβ3, αvβ5 shRNA,
or control shRNA for 24 h, followed by treatment with Cyr61 (10 ng/mL) for 24 h, and cell migration was analyzed using the Transwell assay.
(E and F) MG63 cells were transfected with integrin αvβ3, αvβ5 shRNA, or control shRNA for 24 h, followed by treatment with Cyr61 (10 ng/mL)
for 24 h. Total mRNA and proteins were extracted from the MG63 cells, and expression levels of TWIST-1, N-cadherin and E-cadherin were
detected using qRT-PCR and western blotting. (G) MG63 cells were incubated with Cyr61 (10 ng/mL), osteopontin (10 ng/mL) or MFG-E8
(100 ng/mL) for 24 h, and cell migration was measured using the Transwell assay. (H and I) MG63 Cells were incubated with Cyr61, osteopontin
or MFG-E8 for 24 h. Total mRNA and proteins were extracted from the MG63 cells, and the expression levels of TWIST-1, N-cadherin, and E-cadherin
were detected using qRT-PCR and western blotting. The results are expressed as the mean ± SEM of triplicate samples. *P <0.05 compared with the
control group, and #P <0.05 compared with Cyr61 treatment.
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Figure 4 Cyr61-promoted EMT is mediated by a Raf-1/MEK/ERK signaling cascade. (A) MG63 cells were pretreated with Gw5074, PD98059
or U0126 for 30 min followed by stimulation with Cyr61 (10 ng/mL) for 24 h. Cell migration was measured after 24 h using the Transwell assay.
(B and C) MG63 cells were treated as in (A). Total mRNA and proteins were extracted from the MG63 cells, and the expression levels of TWIST-1,
N-cadherin, and E-cadherin were detected using qRT-PCR and western blotting. (D) MG63 cells were incubated with Cyr61 (10 ng/mL) for the
indicated times, and the phosphorylation of Raf-1, MEK, and ERK was determined through western blotting. (E) MG63 cells were transfected with
Raf-1 shRNA, DN-MEK, DN-ERK, or a control vector for 24 h, followed by treatment with Cyr61 (10 ng/mL) for 24 h, and cell migration was
analyzed using the Transwell assay. (F and G) MG63 cells were treated as in (E). Total mRNA and proteins were extracted from the MG63 cells,
and the expression levels of TWIST-1, N-cadherin, and E-cadherin were detected using qRT-PCR and western blotting. (H) MG63 cells were
pretreated with anti-integrin αvβ3 or αvβ5 mAb (3 μg/mL) for 30 min, followed by stimulation with Cyr61 (10 ng/mL) for 10 min, and Raf-1
phosphorylation was determined with western blotting. (I) MG63 cells were pretreated with Raf-1 inhibitor (Gw5074) (5 μM) for 30 min, followed
by stimulation with Cyr61 (10 ng/mL) for 30 min, and MEK phosphorylation was determined with western blotting. The results are expressed as
the mean ± SEM of triplicate samples. *P <0.05 compared with the control group, and #P <0.05 compared with Cyr61 treatment.
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tion [40]. Our results showed that treating MG63 cells
with Cyr61 increased phosphorylation and the nuclear
translocation of both ERK1/2 and Elk-1 in a time-dependent manner (Figure 5A). Moreover, the transfec-
tion of MG63 cells with Elk-1 shRNA inhibited Cyr61-
mediated cell migration and the shift of EMT markers
(Figure 5 B&C). To confirm whether Elk-1 activation is
Figure 5 Cyr61-promoted EMT is mediated by Elk-1 transcription factor. (A) MG63 cells were incubated with Cyr61 (10 ng/mL) for the
indicated times, the nuclear and cytosol extract were prepared, and the phosphorylation of ERK and Elk-1 was determined with western blotting.
(B) MG63 cells were transfected with Elk-1 shRNA, or a control vector for 24 h, followed by treatment with Cyr61 for 24 h, and cell migration was
analyzed using the Transwell assay. (C) MG63 cells were treated as in (B). Total proteins were extracted from the MG63 cells, and the expression
levels of TWIST-1, N-cadherin, and E-cadherin were detected with western blotting. (D) MG63 cells were pretreated with Gw5074 for 30 min,
followed by stimulation with Cyr61 (10 ng/mL) for 60 min, and the nuclear and cytosol extract were prepared, and ERK phosphorylation was
determined with western blotting. (E) MG63 cells were treated as in (D). Cells were stained with an anti-ERK antibody and analyzed using fluorescence
microscopy. Nuclei were counterstained with DAPI. Representative confocal microscopy images are shown. (F) MG63 cells were pretreated with
Gw5074, PD98059, or U0126 for 30 min, followed by stimulation with Cyr61 (10 ng/mL) for 60 min, the nuclear extract was prepared, and Elk-1
phosphorylation was determined with western blotting. (G) MG63 cells were treated as in (F). Chromatin immunoprecipitation was performed using
anti-Elk-1. Immunoprecipitated chromatin (1%) was assayed to verify equal loading (input). The results are expressed as the mean ± SEM of triplicate
samples. *P <0.05 compared with the control group and #P <0.05 compared with Cyr61 treatment.
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and ERK inhibitors were used. Pretreating cells with
Raf-1 inhibitors (Gw5074) reduced Cyr61-induced ERK
phosphorylation and nuclear translocation (Figure 5
D&E). In addition, these inhibitors (Gw5074, PD98059
and U0126) reduced Cyr61-induced Elk-1 phosphoryl-
ation, nuclear translocation, and the binding of Elk-1 to
an ETS element (Figure 5F&G). Previous studies have
demonstrated that Epithelial–Mesenchymal Transition
Induced by TNF-α. Therefore, we used TNF-α as a posi-
tive control for Elk ChIP assay. These results indicated
that Cyr61-promoted mesenchymal transformation was
mediated via the Raf-1, MEK, ERK, and Elk-1 signaling
pathway.
Knockdown of Cyr61 expression represses mesenchymal
phenotype and inhibits lung metastasis in a mice model
To confirm the role of Cyr61 in osteosarcoma lung me-
tastasis, we exploitedMG63 and U2 OS cells that stablyexpress Cyr61 shRNAs. After puromycin (5 μg/mL) se-
lection, individual stable clones (Cyr61 sh1 and Cyr61
sh2) were collected for analysis. An empty vector plas-
mid was used as the negative control (control sh). The
expression levels of Cyr61 decreased in both Cyr61
shRNA stable clones. Moreover, the expression of mesen-
chymal markers (TWIST-1 and N-cadherin) decreased,
whereas that of the epithelial marker (E-cadherin) in-
creased (Figure 6A-C and Additional file 1: Figure S2 A-E).
The Cyr61 knockdown did not affect the cell proliferation
rate (Figure 6D), but significantly reduced cell migration
(Figure 6E). The lung is the most common site of osteo-
sarcoma metastasis. Therefore, we applied axenograft
mice model to determine whether Cyr61 shRNA reduced
lung metastasis in MG63-injected mice in vivo. Obvious
lung metastases were detected in the mouse lungs. By
contrast, no gross metastasis were observed in mice
injected with the Cyr61-knockdown MG63 (Cyr61 sh2)
(Figure 6F-H). Therefore, the knockdown of Cyr61
Figure 6 Cyr61 knockdown reduces mesenchymal transition and lung metastasis in a mouse model. (A) Total proteins were collected
from MG63 cells stably expressing shRNAs directed against Cyr61. A vector-only control isshown (control sh). Western blot analysis was used to
detect TWIST-1, N-cadherin, and E-cadherin. Actin was used as the loading control. (B-C) Total mRNA was collected from MG63 cells stably
expressing shRNAs, and the expression levels of Cyr61, TWIST-1, N-cadherin and E-cadherin were detected using qRT-PCR. (D) MG63 cells stably
expressing shRNA constructs were seeded as monolayers and were counted daily. Cells (1 × 104) were reseeded after each count, and the cell
numbers were plotted. (E) The in vitro migration of MG63 cells stably expressing shRNA constructs was measured using the Transwell assay.
(F-H) MG63 cells stably expressing control sh and Cyr61 sh2 cells were injected into the tail vein of CB17-SCID mice. After 4 wk, the mice were
sacrificed, and the lung metastatic nodules were photographed and counted. The results are expressed as the mean ± SEM of triplicate samples.
*P <0.05 compared with the control group.
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inhibited lung metastasis in vivo.
Discussion
Osteosarcoma is a high-grade malignant bone neoplasm
that occurs mainly in children and adolescents. The
chemotherapy regimens are not considerably effective,
and result in the death of 20% of all patients because of
lung metastasis. Therefore, developing an effective adju-
vant therapy for preventing osteosarcoma metastasis is
critical. EMT has received considerable attention as aconceptual paradigm for explaining invasive and meta-
static behavior during cancer progression [5]. In this
study, we determined that Cyr61 induced EMT and pro-
moted lung metastasis in osteosarcoma. Moreover, Cyr61-
induced EMT was mediated by an integrin αvβ5 receptor
and the Raf-1, ERK, and Elk-1 signaling pathways.
In the past decade, Cyr61 has been implicated in osteo/
chondrogenesis. It promotes chondrogenic differentiation
through the expression of type II collagen [41]. In
addition, Cyr61 expression promotes osteogenesis by in-
creasing osteoblast differentiation and inhibiting osteoclast
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osteogenesis, aberrant levels or altered forms of CCN pro-
teins are associated with osteosarcoma progression. The
Cyr61 expression level is correlated with a poor prognosis
in osteosarcoma specimens, irrespective of whether the
disease is metastatic [33]. Moreover, Cyr61 expression was
higher in patients with primary osteosarcoma than in
those with normal bones, and was highly expressed in
metastatic specimens. The knockdown of Cyr61 inhibited
in vitro osteosarcoma cell invasion and migration as well
as in vivo lung metastasis in mice [43]. These results
showed a great opportunity for Cyr61 to be used as a
novel prognosis marker and therapeutic target in osteosar-
coma. Consistent with previous studies, the current study
showed that Cyr61 promoted cell migration and lung me-
tastasis through EMT in osteosarcoma (Figure 2 and 6).
The Cyr61 protein promoted mesenchymal transformation
by upregulating mesenchymal markers (TWIST-1 and N-
cadherin) and repressing the epithelial marker (E-cadherin).
This study revealed a new molecular mechanism that eluci-
dates the role of Cyr61 in osteosarcoma progression.
Integrin is the most cruciall cell surface regulator that
links the extracellular matrix to intracellular signaling
molecules, and could regulate numerous cellular bio-
logical functions such as cell adhesion, signaling, motil-
ity, survival, gene expression, growth, and differentiation.
Most studies have shown that Cyr61 exerts its function by
directly binding to integrins [18,44]. In this study, Cyr61-
induced mesenchymal transformation was mediated by
integrin αvβ5, but not by αvβ3. Moreover, treating osteosar-
coma cells with the anti-αvβ5 integrin antibody inhibited
Cyr61-induced mesenchymal transformation (Figure 2).
The integrin αvβ3 and αvβ6 antibodies have been impli-
cated in lung and oral cancers [45,46]. However, this paper
is the first to present a discussion on the role of integrin
αvβ5 in EMT.
Several intracellular signaling proteins such as the re-
ceptor tyrosine kinase family [47], small GTPase family,
and MAPK family [48] are implicated in the process of
EMT. In the MAPK family, ERK, JNK, and p38 promote
EMT by repressing the expression of E-cadherin through
distinct mechanisms [49-51]. In this study, we determined
that Cyr61 promoted mesenchymal transformation in
osteosarcoma through the Raf-1/MEK/ERK signaling cas-
cade (Figure 4). Both pathway inhibitors and dominant
mutants could reduce the Cyr61-promoted mesenchymal
transformation in osteosarcoma cells. Transforming growth
factor-β (TGF-β), a multifunctional cytokine regulating
various cellular processes, is a well-discussed EMT in-
ducer. The TGF-β activates various signaling proteins such
as Smads, phosphatidylinositol 3-kinase, and MAPK to
regulate EMT [52]. Our investigation showed that the
MEK/ERK signaling pathway mediated Cyr61-induced
EMT, suggesting that the other MAPK members mayparticipate in this transition. Additional efforts will be
expended to determine the detailed mechanism involved
in Cyr61-induced EMT in osteosarcoma.
The Elk-1 belongs to the ETS-domain transcription
factor family, which regulates cell growth, differentiation,
and survival. However, recent studies have revealed that
Elk-1 modulates the genes involved in transcript turn-
over and cell migration [53]. By regulating the genes,
such as plasminogen activator-1 and metalloproteinases-
2 and -9, Elk-1 plays a crucial role in cancer progression.
Numerous studies have indicated that Elk-1 is involved in
the progression of several cancers. The Elk-1 is required
for androgen-receptor-dependent growth and the survival
of prostate cancer cells [54]. The Elk-1 controls cell migra-
tion by targeting various genes [55] or by regulating cell
survival [56] in breast cancer. Altough the correlation be-
tween Elk-1 and cancer progression has been strength-
ened, we examined the role of Elk-1 in EMT for the first
time in this study. The Raf-1/MEK/ERK signaling cascades
activated downstream transcription factor Elk-1, and thus,
participated in Cyr61-induced EMT (Figure 5). The mo-
lecular mechanism involved in Elk-1-regulated EMT will
be investigated in the future.
Cancer metastasis, the major cause of mortality in can-
cer patients, comprises several steps through which cells
detach from the primary tumor and form a secondary
tumor at a distant site [57]. Abundant evidence for EMT
associated with metastasis has been provided in recent
studies [7]. To determine the effect of Cyr61 on osteo-
sarcoma progression directly, we knocked down Cyr61
expression in MG63 cells by using shRNA (Figure 6).
The Cyr61 knockdown significantly reduced mesenchy-
mal markers, induced epithelial marker expression, and
inhibited migration in MG63 cells. Finally, the transition
of the cell phenotype inhibited lung metastasis. These
data indicated that Cyr61 plays a crucial role in osteosar-
coma metastasis to the lung in vivo.
Because lung metastasis is the major cause in mortality
of patients with late-stage osteosarcoma, identifying the
tumor-related factors involved in cancer metastasis is crit-
ical. In this study, we gained new insights into the Cyr61
function and its role in osteosarcoma progression. The
Cyr61 expression was correlated with cell migratory po-
tential in osteosarcoma cells, and its upregulation pro-
motes EMT and tumor metastasis in vivo. Moreover, the
Cyr61-promoted mesenchymal transition was mediated by
the integrin αvβ5, Raf-1, MEK, ERK, and Elk-1 signaling
pathways. Our observation provides a novel opportunity
for treating osteosarcoma by targeting the Cyr61 gene.
Materials and methods
Material
Protein A/G beads, antimouse and antirabbit IgG-
conjugated horseradish peroxidase, rabbit polyclonal
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E-cadherin, p-Raf-1, Raf-1, p-ERK, ERK, p-MEK, MEK,
p-Elk, Elk, PCNA and β-Actin were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit poly-
clonal antibodies specific for αvβ3 and αvβ5 integrin were
purchased from Chemicon (Temecula, CA, USA). The re-
combinant human Cyr61, osteopontin and MFGE-8 were
purchased from PeproTech (Rocky Hill, NJ, USA). All of
the shRNAs plasmids used for gene knock down were
purchased from the National RNAi Core Facility Platform
(Taipei, Taiwan). All of the other chemicals were obtained
from Sigma-Aldrich (St Louis, MO, USA).
Cell culture
The human osteosarcoma cell line MG63 was purchased
from the American Type Cell Culture Collection (Manassas,
VA, USA). The cells were maintained in Dulbecco’s
Modified Eagle’s Medium, which was supplemented with
20 mM HEPES, 10% heat-inactivated fetal bovine serum,
2 mM-glutamine, penicillin (100 U/mL), and streptomycin
(100 μg/mL), at 37°C with 5% CO2.
To establish the Cyr61 stable knockdown MG63 cell
line, Cyr61 shRNA plasmids were purchased from the
National RNAi Core Facility Platform (Taipei, Taiwan).
The Cyr61 shRNA plasmids were transfected with Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA, USA) and
Cyr61 shRNA-expressing cells were puromycin selected
(10 μg/mL). The surviving cells were selected and ex-
panded to produce clonal cell populations. For mono-
layer growth curves, 104 cells were plated in 6-well
plates and grown for 1–3 days. The cells were trypsi-
nized, and the cell numbers were counted daily.
Establishment of migration-prone sublines
The subpopulations from MG63 cells were selected ac-
cording to their differential migration ability [58]; the
cell culture insert system was used as described. After
24 h of migration, cells that penetrated pores and mi-
grated to the underside of the filters were trypsinized
and harvested for a second round of selection. The ori-
ginal cells that did not penetrate membrane pores were
designated as M0. After 10 rounds of selection, the
migration-prone subline was designated as M10.
Migration assay
The migration assay was performed using the Transwell
assay (Costar, NY, USA; pore size: 8 μm) in 24-well dishes.
Before the migration assay, the cells were pretreated with
different concentrations of inhibitors, including Gw5047,
PD98059, U0126, and the vehicle control (0.1% DMSO),
or neutralized antibodies such as Cyr61, αvβ3, and αvβ5
integrin, and the vehicle control (IgG) for 30 min, or they
were transfected with the indicated shRNA plasmids, in-
cluding the TWIST-1, integrin αv, integrin β5, Raf-1, andElk-1 for 24 h. After pretreatment, approximately 1 × 104
cells in 200 μL of a serum-free medium were placed in the
upper chamber, and 300 μL of the same medium contain-
ing Cyr61, osteopontin or MFGE-8 was placed in the
lower chamber. The plates were incubated for 24 h at
37°C in 5% CO2, and then the cells were fixed in methanol
for 15 min and stained with 0.05% crystal violet in PBS for
15 min. The cells on the upper side of the filters were re-
moved with cotton-tipped swabs, and the filters were
washed with PBS. The cells on the underside of the filters
were examined and counted using a microscope. Each ex-
periment was repeated at least 3 times. The number of in-
vading cells in each experiment was adjusted using the
cell viability assay to correct for the proliferation effects
of Cyr61 treatment (corrected invading cell number =
counted invading cell number/percentage of viable cells).
Wound-healing assay
For wound-healing migration assays, the cells were seeded
on 12-well plates at a density of 2 × 105 cells/ per well in a
culture medium. At 24 h after seeding, the cells were
treated with the indicated inhibitors or a neutralized anti-
bodies for 30 min or transfected with shRNA plasmids for
24 h. After pretreatment, the confluent monolayer of the
culture was scratched using a fine pipette tip, and incu-
bated with recombinant Cyr61 for 24 h and migration was
observed using microscopy. The rate of wound closure
was observed at the indicated times.
Quantitative real-time polymerase chain reaction
Quantitative real-time polymerase chain reaction (qRT-
PCR) analysis was performed using Taqman® one-step
PCR Master Mix (Applied Biosystems, Foster City CA,
USA). Furthermore, 100 ng of total cDNA was added to
every 25-μL reaction with sequence-specific primers and
Taqman® probes. The sequences for all target gene primers
and probes were purchased commercially (β-actin was
used as the internal control) (Applied Biosystems, Foster
City CA, USA). The qRT-PCR assays were conducted in
triplicate on a StepOnePlus sequence detection system.
The cycling conditions were 10-min of polymerase acti-
vation at 95°C, followed by 40 cycles at 95°C for 15 s and
60°C for 60 s. The threshold was set higher than the non-
template control background and within the linear phase
of target gene amplification for calculating the cycle
number at which the transcript was detected (denoted
as CT).
Western blot analysis
The celllysates were prepared, and proteins were then
resolved on sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, and transferred to Immobilon polyvinyl-
difluoride membranes. The blots were blocked with 4%
BSA for 1 h at room temperature and then probed with
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N-cadherin, E-cadherin, p-Raf-1, Raf-1, p-ERK, ERK,
p-MEK, MEK, p-Elk, and β-Actin (1:1000) for 1 h at
room temperature. After 3 washes, the blots were subse-
quently incubated with a donkey antirabbit peroxidase-
conjugated secondary antibody (1:1000) for 1 h at room
temperature. The blots were observed using enhanced
chemiluminescence by employing Kodak X-OMAT LS
film (Eastman Kodak, Rochester, NY, USA). Quantitative
data were obtained using a computing densitometer and
ImageQuant software (Molecular Dynamics, Sunnyvale,
CA, USA).
Nuclear extracts were prepared as described previously
[58]. The cells were suspended in buffer A for 10 min
on ice. The lysates were separated into cytosolic and nu-
clear fractions through centrifugation at 12000 g for
10 min. The supernatants containing cytosolic proteins
were collected. A pellet containing nuclear fractions was
resuspended in buffer C for 30 min on ice. The superna-
tants containing nuclear proteins were collected through
centrifugation at 13 000 g for 20 min, and stored at -80°C.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation analysis was performed
as described previously [59]. DNA immunoprecipitated
using the anti-Elk antibody was purified. The DNA was
then extracted using phenol–chloroform. The purified
DNA pellet was subjected to PCR, and the PCR prod-
ucts were then resolved by conducting 1.5% agarose gel
electrophoresis, and they were observed using ultraviolet.
The primers 5′-AGCCCCAGCAATCCAAATC-3′ and
5′-TCGGAGGAGACTGTCCTGG-3′ were used for amp-
lification across the human TWIST-1 promoter region
(1466 to 1613).
Immunofluorescence microscopy
The MG63 cells grown on glass coverslips were rinsed
once with PBS, and fixed in 3.7% paraformaldehyde for
10 min in RT. The cells were then washed 3 times with
PBS, and blocked with 4% BSA for 15 min. The cells
were then incubated with rabbit antimouse Elk (1:100)
for 1 h in RT, rewashed, and incubated with FITC-
conjugated goat anti-rabbit IgG for 1 h. Finally, the cells
were washed, mounted, and examined using a Leica TCS
SP2 Spectral Confocal System.
In vivo tumor xenograft study
Four-week-old male SCID mice were purchased from
Lasco (Taipei, Taiwan) and maintained under pathogen-
free conditions. All of the animal experiments were per-
formed according to a protocol approved by the Shin
Kong Wu Ho-Su Memorial Hospital (Taipei, Taiwan)
Institutional Animal Care and Use Committee. Male
CB17/SCID mice (4 wk old) were used. Seven animalsper group, were used, and the experiment was repeated
twice. For experimental metastasis assays, 1 × 106 cells
were resuspended in 0.1 mL of PBS, and injected into
the lateral tail vein. After 4 wk, the mice were eutha-
nized using an overdose of the anesthetic agent. The
lungs were removed and fixed in 10% formalin. The
number of lung tumor metastases was counted using a
dissecting microscope.Statistical analysis
Data are presented as the mean ± standard error of the
mean (SEM). Statistical comparisons between two sam-
ples were performed using Student’s t test. Statistical
comparisons of more than 2 groups were performed
using one-way analysis of variance with Bonferroni’s post
hoc test. A P-value less than 0.05 was considered statisti-
cally significant.Additional file
Additional file 1: Cyr61 expression level in human fetal osteoblastic
cell line compared with osteosarcoma cell lines. Figure S1. The
expression of Cyr61 in human osteosarcoma cells. (A-B) Total protein and
mRNA were extracted form hFOB 1.19, U2 OS, and U2OS cells, the Cyr61
expression was examined by western blot analysis and qPCR. Results are
expressed as the mean ± SEM. *p < 0.05 compared with hFOB 1.19.
Knockdown of Cyr61 expression represses mesenchymal phenotype and
inhibits cell migration in U-2 OS cell line. Figure S2. Cyr61 knockdown
reduces mesenchymal transition in U2 OS cell lins. (A) Total proteins were
collected from U2 OS cells stably expressing shRNAs directed against
Cyr61. A vector-only control is shown (control sh). Western blot analysis
was used to detect Cyr61, TWIST-1, N-cadherin, and E-cadherin. Actin was
used as the loading control. (B-C) Total mRNA was collected from U2 OS
cells stably expressing shRNAs, and the expression levels of Cyr61,
TWIST-1, N-cadherin and E-cadherin were detected using qRT-PCR. (D) U2
OS cells stably expressing shRNA constructs were seeded as monolayers
and were counted daily. Cells (1 × 104) were reseeded after each count,
and the cell numbers were plotted. (E) The in vitro migration of U2 OS
cells stably expressing shRNA constructs was measured using the
Transwell assay. Results are expressed as the mean ± SEM. *p < 0.05
compared with control sh.
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